Previous 10 | Next 10 |
Generation Investment Management's 13F portfolio value decreased from $24.33B to $21.84B this quarter. They increased Equifax, Clarivate Plc, Trane Technologies, Twilio, and Salesforce while reducing Dentsply Sirona & Sensata Technologies. The top three positions are Amazon.co...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips After hitting new lows, the stock market roared back with all the major indices posting gains last week. The S&P 500 , Dow Jones Industrial Average and NASDAQ Composite ended the week up 6.6%, 6.2%, and 6.8%, respe...
Abiomed, Inc . (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present (live) at the William Blair 42 nd Annual Growth Stock Conference on Monday,...
Abiomed (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock (AMICS) patients during the Society fo...
ABMD had a decent quarter where revenues grew nicely but profits languished due to sudden growth in R&D spend. Companies like ABMD have to expense R&D, which is not a problem, but a lack of profit growth isn't great given its valuation. The multiple doesn't offer much of a...
The management team at Insulet Corporation is due to report financial data for the first quarter of the company's 2022 fiscal year. Growth should come in strong, just as it has in prior years, and the long-term outlook for Insulet looks favorable. But PODD shares are far too price...
Abiomed, Inc. (ABMD) Q4 2022 Results Conference Call April 28, 2022 08:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Michael Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Matthew O...
The following slide deck was published by Abiomed, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Abiomed, Inc. 2022 Q4 - Results - Earnings Call Presentation
Abiomed press release (NASDAQ:ABMD): Q4 Non-GAAP EPS of $1.16 beats by $0.11. Revenue of $270M (+11.9% Y/Y) beats by $2.33M. For further details see: Abiomed Non-GAAP EPS of $1.16 beats by $0.11, revenue of $270M beats by $2.33M
FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022. Financial summ...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...